Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33


RhoB blockade selectively inhibits autoantibody production in autoimmune models of rheumatoid arthritis and lupus.

Mandik-Nayak L, DuHadaway JB, Mulgrew J, Pigott E, Manley K, Sedano S, Prendergast GC, Laury-Kleintop LD.

Dis Model Mech. 2017 Nov 1;10(11):1313-1322. doi: 10.1242/dmm.029835. Epub 2017 Sep 7.


Therapeutic antibody targeting of indoleamine-2,3-dioxygenase (IDO2) inhibits autoimmune arthritis.

Merlo LMF, Grabler S, DuHadaway JB, Pigott E, Manley K, Prendergast GC, Laury-Kleintop LD, Mandik-Nayak L.

Clin Immunol. 2017 Jun;179:8-16. doi: 10.1016/j.clim.2017.01.016. Epub 2017 Feb 20.


IDO2: A Pathogenic Mediator of Inflammatory Autoimmunity.

Merlo LM, Mandik-Nayak L.

Clin Med Insights Pathol. 2016 Nov 21;9(Suppl 1):21-28. eCollection 2016. Review.


IDO2 Modulates T Cell-Dependent Autoimmune Responses through a B Cell-Intrinsic Mechanism.

Merlo LM, DuHadaway JB, Grabler S, Prendergast GC, Muller AJ, Mandik-Nayak L.

J Immunol. 2016 Jun 1;196(11):4487-97. doi: 10.4049/jimmunol.1600141. Epub 2016 Apr 25.


IDO2 in Immunomodulation and Autoimmune Disease.

Prendergast GC, Metz R, Muller AJ, Merlo LM, Mandik-Nayak L.

Front Immunol. 2014 Nov 20;5:585. doi: 10.3389/fimmu.2014.00585. eCollection 2014. Review.


1-Methyl-tryptophan synergizes with methotrexate to alleviate arthritis in a mouse model of arthritis.

Pigott E, DuHadaway JB, Muller AJ, Gilmour S, Prendergast GC, Mandik-Nayak L.

Autoimmunity. 2014 Sep;47(6):409-18. doi: 10.3109/08916934.2014.914507. Epub 2014 May 6.


Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer.

Prendergast GC, Smith C, Thomas S, Mandik-Nayak L, Laury-Kleintop L, Metz R, Muller AJ.

Cancer Immunol Immunother. 2014 Jul;63(7):721-35. doi: 10.1007/s00262-014-1549-4. Epub 2014 Apr 8. Review.


IDO2 is a critical mediator of autoantibody production and inflammatory pathogenesis in a mouse model of autoimmune arthritis.

Merlo LMF, Pigott E, DuHadaway JB, Grabler S, Metz R, Prendergast GC, Mandik-Nayak L.

J Immunol. 2014 Mar 1;192(5):2082-2090. doi: 10.4049/jimmunol.1303012. Epub 2014 Jan 31.


IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation.

Metz R, Smith C, DuHadaway JB, Chandler P, Baban B, Merlo LM, Pigott E, Keough MP, Rust S, Mellor AL, Mandik-Nayak L, Muller AJ, Prendergast GC.

Int Immunol. 2014 Jul;26(7):357-67. doi: 10.1093/intimm/dxt073. Epub 2014 Jan 8.


IDO is a nodal pathogenic driver of lung cancer and metastasis development.

Smith C, Chang MY, Parker KH, Beury DW, DuHadaway JB, Flick HE, Boulden J, Sutanto-Ward E, Soler AP, Laury-Kleintop LD, Mandik-Nayak L, Metz R, Ostrand-Rosenberg S, Prendergast GC, Muller AJ.

Cancer Discov. 2012 Aug;2(8):722-35. doi: 10.1158/2159-8290.CD-12-0014. Epub 2012 Jul 19.


Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases.

Prendergast GC, Chang MY, Mandik-Nayak L, Metz R, Muller AJ.

Curr Med Chem. 2011;18(15):2257-62. doi: 0929-8673/11 $58.00+.00. Review.


Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion.

Muller AJ, DuHadaway JB, Chang MY, Ramalingam A, Sutanto-Ward E, Boulden J, Soler AP, Mandik-Nayak L, Gilmour SK, Prendergast GC.

Cancer Immunol Immunother. 2010 Nov;59(11):1655-63. doi: 10.1007/s00262-010-0891-4. Epub 2010 Jul 17.


Beyond immunosuppression: reconsidering indoleamine 2,3-dioxygenase as a pathogenic element of chronic inflammation.

Muller AJ, Mandik-Nayak L, Prendergast GC.

Immunotherapy. 2010 May;2(3):293-7. doi: 10.2217/imt.10.22. No abstract available. Erratum in: Immunotherapy. 2010 Jul;2(4):590.


The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity.

Scott GN, DuHadaway J, Pigott E, Ridge N, Prendergast GC, Muller AJ, Mandik-Nayak L.

J Immunol. 2009 Jun 15;182(12):7509-17. doi: 10.4049/jimmunol.0804328.


High affinity glycosaminoglycan and autoantigen interaction explains joint specificity in a mouse model of rheumatoid arthritis.

Studelska DR, Mandik-Nayak L, Zhou X, Pan J, Weiser P, McDowell LM, Lu H, Liapis H, Allen PM, Shih FF, Zhang L.

J Biol Chem. 2009 Jan 23;284(4):2354-62. doi: 10.1074/jbc.M806458200. Epub 2008 Oct 22.


DNA double-strand breaks activate a multi-functional genetic program in developing lymphocytes.

Bredemeyer AL, Helmink BA, Innes CL, Calderon B, McGinnis LM, Mahowald GK, Gapud EJ, Walker LM, Collins JB, Weaver BK, Mandik-Nayak L, Schreiber RD, Allen PM, May MJ, Paules RS, Bassing CH, Sleckman BP.

Nature. 2008 Dec 11;456(7223):819-23. doi: 10.1038/nature07392. Epub 2008 Oct 12.


Role of B cells in systemic lupus erythematosus and rheumatoid arthritis.

Mandik-Nayak L, Ridge N, Fields M, Park AY, Erikson J.

Curr Opin Immunol. 2008 Dec;20(6):639-45. doi: 10.1016/j.coi.2008.08.003. Epub 2008 Sep 18.


Elevated ornithine decarboxylase levels activate ataxia telangiectasia mutated-DNA damage signaling in normal keratinocytes.

Wei G, DeFeo K, Hayes CS, Woster PM, Mandik-Nayak L, Gilmour SK.

Cancer Res. 2008 Apr 1;68(7):2214-22. doi: 10.1158/0008-5472.CAN-07-5030.


The MAPK scaffold kinase suppressor of Ras is involved in ERK activation by stress and proinflammatory cytokines and induction of arthritis.

Fusello AM, Mandik-Nayak L, Shih F, Lewis RE, Allen PM, Shaw AS.

J Immunol. 2006 Nov 1;177(9):6152-8.


Autoreactive marginal zone B cells are spontaneously activated but lymph node B cells require T cell help.

Mandik-Nayak L, Racz J, Sleckman BP, Allen PM.

J Exp Med. 2006 Aug 7;203(8):1985-98. Epub 2006 Jul 31.


Initiation of an autoimmune response: insights from a transgenic model of rheumatoid arthritis.

Mandik-Nayak L, Allen PM.

Immunol Res. 2005;32(1-3):5-13. Review.


Massive thymic deletion results in systemic autoimmunity through elimination of CD4+ CD25+ T regulatory cells.

Shih FF, Mandik-Nayak L, Wipke BT, Allen PM.

J Exp Med. 2004 Feb 2;199(3):323-35. Epub 2004 Jan 26.


B cell anergy and systemic lupus erythematosus.

Seo SJ, Mandik-Nayak L, Erikson J.

Curr Dir Autoimmun. 2003;6:1-20. Review. No abstract available.


Despite ubiquitous autoantigen expression, arthritogenic autoantibody response initiates in the local lymph node.

Mandik-Nayak L, Wipke BT, Shih FF, Unanue ER, Allen PM.

Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14368-73. Epub 2002 Oct 21.


The impact of T helper and T regulatory cells on the regulation of anti-double-stranded DNA B cells.

Seo SJ, Fields ML, Buckler JL, Reed AJ, Mandik-Nayak L, Nish SA, Noelle RJ, Turka LA, Finkelman FD, Caton AJ, Erikson J.

Immunity. 2002 Apr;16(4):535-46.


Alterations in splenic architecture and the localization of anti-double-stranded DNA B cells in aged mice.

Eaton-Bassiri AS, Mandik-Nayak L, Seo SJ, Madaio MP, Cancro MP, Erikson J.

Int Immunol. 2000 Jun;12(6):915-26.


The origin of anti-nuclear antibodies in bcl-2 transgenic mice.

Mandik-Nayak L, Nayak S, Sokol C, Eaton-Bassiri A, Madaio MP, Caton AJ, Erikson J.

Int Immunol. 2000 Mar;12(3):353-64.


Functional consequences of the developmental arrest and follicular exclusion of anti-double-stranded DNA B cells.

Mandik-Nayak L, Seo Sj, Eaton-Bassiri A, Allman D, Hardy RR, Erikson J.

J Immunol. 2000 Feb 1;164(3):1161-8.


MRL-lpr/lpr mice exhibit a defect in maintaining developmental arrest and follicular exclusion of anti-double-stranded DNA B cells.

Mandik-Nayak L, Seo SJ, Sokol C, Potts KM, Bui A, Erikson J.

J Exp Med. 1999 Jun 7;189(11):1799-814.


Characterization of anergic anti-DNA B cells: B cell anergy is a T cell-independent and potentially reversible process.

Noorchashm H, Bui A, Li HL, Eaton A, Mandik-Nayak L, Sokol C, Potts KM, Puré E, Erikson J.

Int Immunol. 1999 May;11(5):765-76.


Regulation of anti-double-stranded DNA B cells in nonautoimmune mice: localization to the T-B interface of the splenic follicle.

Mandik-Nayak L, Bui A, Noorchashm H, Eaton A, Erikson J.

J Exp Med. 1997 Oct 20;186(8):1257-67.

Supplemental Content

Loading ...
Support Center